Merck, Bayer’s heart failure therapy Verquvo now approved for use across Europe

WORLD – Verquvo, a drug developed for the treatment of symptomatic chronic heart failure has been cleared for use by the European Commission (EC). The approval reflects another important regulatory milestone in the development of the medicine which will provide doctors, health care professionals and patients with an important treatment option to complement currently available heart failure therapies. Merck and Bayer jointly co-developed Verquvo with Merck holding the commercial rights to the heart failure drug in the US and Bayer having exclusive commercial rights globally. The drug relayed successful data…

Read More

Bayer’s Kerendia can now be used in USA as therapy for chronic kidney disease in type 2 diabetes patients

US – Bayer’s first-in-class nonsteroidal drug Kerendia is now available in the US for use following an approval as a therapy that can slow chronic kidney disease progression in patients with type 2 diabetes. The approval is based on data from the Phase III FIDELIO-DKD renal outcomes study, which showed Kerendia significantly reduced the combined primary endpoint of chronic kidney disease progression, kidney failure or kidney death versus placebo when added to standard of care. Kerendia also lowered the risk of a composite of time to first occurrence of cardiovascular…

Read More

Merck and BioMedX set to partner as they strive to bolster their fight against cancer in a new joint cancer research programme

GERMANY – German based pharma company, Merck, and BioMed X, an independent research institute located at the University of Heidelberg in Germany have partnered to focus on their oncology related research. This is the eighth collaboration between the two organizations and is set to explore the role of extrachromosomal DNA (ecDNA) in cancer. BioMedX currently has two other ongoing oncology related programmes focused on DNA damage response and RNA splicing that this new research program is set to compliment. Extrachromosomal DNA (ecDNA) is any DNA that is found off the…

Read More

Cadila, Bayer joint venture partnership gets a three-year extension

INDIA – Zydus Cadila, a leading Indian Pharmaceutical company and Bayer (South East Asia), a subsidiary in Singapore that deals in distribution of prescription drugs, have decided to extend their joint venture by three years with effect from June. The two companies first entered into the joint venture agreement ten years ago with a joint name Bayer Zydus Pharma and operated mainly from Mumbai with a business model revolving around the sales and marketing of pharmaceutical products in India and across the world. During the previous joint venture, Bayer’s global…

Read More

Bayer’s Astepro approved for over the counter use in the US

US – The US Food and Drug Administration (FDA) has approved Bayer’s steroid-free antihistamine nasal spray Astepro for over-the-counter use. Astepro becomes the first and only OTC steroid-free antihistamine nasal spray available in the US for adults and children aged six years and older. Currently, OTC allergy medications is classified into three major classes which include antihistamines, intranasal steroids and mast cell stabilizers. Bayer, a German multinational pharmaceutical and life sciences company had astepro previously approved for prescription use in 2008. Following the approval by the FDA, Astepro will be…

Read More

Lupin launches digital asthma educator platform in India

INDIA – Drug major Lupin has announced the launch of its digital asthma educator platform to guide patients on the correct technique of using inhalers. The new platform is the latest initiative under Lupin’s long-running umbrella program, “Joint Airways Initiative” (JAI), for patients suffering from respiratory ailments. Lupin said, according to estimates, India has nearly 35 million people living with asthma, including children. While there is no cure for asthma, it is manageable with proper treatment, vigilance, drug adherence, and regular medical checks, thus enabling patients to lead a normal…

Read More